Scarica l'app Stockscreener
26.87
4.61%
1.185
Dopo l'orario di chiusura:
26.92
0.05
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - Yahoo Finance
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - TradingView
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Placera.se
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.12 per Share, vs. FactSet Est of $-0.10 - MarketScreener
Summit Therapeutics Inc. SEC 10-Q Report - TradingView
Pattern recognition hints at Summit Therapeutics Inc. upsideFree AI Driven Stock Trend Forecast - Newser
Visual trend scoring systems applied to Summit Therapeutics Inc.Free Weekly Stock Watch With Growth Focus - Newser
Summit Therapeutics Inc. recovery potential after sell offChart Driven Entry Timing for Swing Trades - Newser
Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial - TipRanks
Traders Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT) - Defense World
ETFs and Analyst Targets: iShares Russell 1000 Growth ETF has 10% Upside - AInvest
Summit Therapeutics' Flawed Buy Thesis and the Missing Link in Oncology Data - AInvest
Summit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is Flawed (NASDAQ:SMMT) - Seeking Alpha
Published on: 2025-08-05 22:22:23 - Newser
Cwm LLC Increases Position in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Using data tools to time your Summit Therapeutics Inc. exitTrend Analysis for Safer Market Entries - Newser
Using portfolio simulators with Summit Therapeutics Inc. includedTechnical Reversal Setup with Risk Limits - Newser
Best data tools to analyze Summit Therapeutics Inc. stockFast Movement Forecast for Trading Success - Newser
Institutional scanner results for Summit Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Summit Therapeutics Q3 2024 slides: Ivonescimab shows superior PFS vs. pembrolizumab - Investing.com Canada
Published on: 2025-08-04 09:17:43 - metal.it
Summit Therapeutics Skyrockets 7.22% – What’s Fueling This Biotech Surge? - AInvest
Advanced analytics toolkit walkthrough for Summit Therapeutics Inc.Weekly Price Target Forecast and Alerts - Newser
How hedge fund analytics apply to Summit Therapeutics Inc. stockHigh Conviction Stock Long-Term Summary - Newser
How volatile is Summit Therapeutics Inc. stock compared to the marketDiscover breakthrough stocks with expert help - Jammu Links News
Is Summit Therapeutics Inc. stock a growth or value playMarket Liquidity and Price Flow Analysis - Newser
What analysts say about Summit Therapeutics Inc. stockRecord-breaking gains - Jammu Links News
What is Summit Therapeutics Inc. company’s growth strategyBuild a diversified portfolio for steady growth - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionTremendous growth opportunities - Jammu Links News
Published on: 2025-08-03 16:05:04 - Jammu Links News
How does Summit Therapeutics Inc. generate profit in a changing economyExtraordinary profit generation - Jammu Links News
Does Summit Therapeutics Inc. stock perform well during market downturnsSuperior return velocity - Jammu Links News
What are the latest earnings results for Summit Therapeutics Inc.Capitalize on market momentum for big wins - Jammu Links News
Can Summit Therapeutics Inc. rally from current levelsLow Drawdown Picks with Weekly Updates - newser.com
Strategies to average down on Summit Therapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
Commit To Buy Summit Therapeutics At $18, Earn 30.8% Annualized Using Options - Nasdaq
What’s the recovery path for long term holders of Summit Therapeutics Inc.Free Buy Signal Based on Chart Analysis - Newser
How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser
Advanced analytics toolkit walkthrough for Tyra Biosciences Inc.Free Low Drawdown Real Time Trading Tips - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser
What are the technical indicators suggesting about Summit Therapeutics Inc.High-yield growth strategies - Jammu Links News
5.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):